$CTOR
CITIUS ONCOLOGY, INC. Stock $ctor

$ctor Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224030991 Filed on August 09, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses
YoY Change
Operating Profit		-$384.0K
YoY Change		92.41%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		$636.4K
YoY Change		-21.99%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings		$252.5K
YoY Change		-59.04%
Net Earnings / Revenue
Basic Earnings Per Share		$0.04
Diluted Earnings Per Share		$0.04
COMMON SHARES
Basic Shares Outstanding	2.355M shares	6.653M shares
Diluted Shares Outstanding		4.312M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$261.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses		$40.73K
Receivables
Other Receivables
Total Short-Term Assets		$40.99K
YoY Change		-91.13%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$49.15M
YoY Change		-29.16%
TOTAL ASSETS
Total Short-Term Assets		$40.99K
Total Long-Term Assets		$49.15M
Total Assets		$49.19M
YoY Change		-29.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses		$485.8K
YoY Change		346.06%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$3.081M
YoY Change		564.17%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$3.081M
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings		-$3.040M
YoY Change		137461.86%
Common Stock		$167.00
YoY Change		-30.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$3.040M
YoY Change
Total Liabilities & Shareholders Equity		$49.19M
YoY Change		-29.57%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income		$252.5K
YoY Change		-59.04%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022Q4	TENK	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
	dei	Entity Central Index Key EntityCentralIndexKey	0001851484
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41534
	dei	Entity Registrant Name EntityRegistrantName	CITIUS ONCOLOGY, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Address Address Line1 EntityAddressAddressLine1	420 Lexington Ave
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2446
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10170
	dei	City Area Code CityAreaCode	(347)
	dei	Local Phone Number LocalPhoneNumber	627-0058
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2355249	shares
CY2024Q2	us-gaap	Cash Cash	261	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	40988	usd
CY2024Q2	us-gaap	Long Term Investments LongTermInvestments	49152639	usd
CY2024Q2	us-gaap	Assets Assets	49193627	usd
CY2024Q2	TENK	Accrued Offering Costs AccruedOfferingCosts	5001	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	485750	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	1720001	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-347476	usd
CY2024Q2	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust	636419	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zwvsoEuw5PC2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z1geVEvuXSAe">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	67320000	usd
CY2024Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.20
CY2024Q2	TENK	Investments Held In Trust Account InvestmentsHeldInTrustAccount	49152639	usd
CY2023Q4	TENK	Investments Held In Trust Account InvestmentsHeldInTrustAccount	72565394	usd
CY2024Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	TENK	Proceeds From Cash Withdrawn From Trust Account ProceedsFromCashWithdrawnFromTrustAccount		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	TENK	Payments For Relation To Redemptions Of Ordinary Shares PaymentsForRelationToRedemptionsOfOrdinaryShares		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.0001
CY2023Q4	us-gaap	Cash Cash	32746	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	40727	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	25454	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	58200	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	72565394	usd
CY2023Q4	us-gaap	Assets Assets	72623594	usd
CY2023Q4	TENK	Accrued Offering Costs AccruedOfferingCosts	5001	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	375886	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1320000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3080938	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2045762	usd
CY2024Q2	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	4312077	shares
CY2023Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	6600000	shares
CY2024Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	11.35
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	10.99
CY2024Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	49152639	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	72565394	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2341000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2341000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2341000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2341000	shares
CY2024Q2	TENK	Common Stock Shares Subject To Mandatory Redemption Number Of Shares CommonStockSharesSubjectToMandatoryRedemptionNumberOfShares	4312077	shares
CY2023Q4	TENK	Common Stock Shares Subject To Mandatory Redemption Number Of Shares CommonStockSharesSubjectToMandatoryRedemptionNumberOfShares	6600000	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	167	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	167	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3040117	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1987729	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-3039950	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1987562	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49193627	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	72623594	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	383957	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	199554	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	652386	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	347476	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-383957	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-199554	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-652386	usd
CY2023Q2	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust	815850	usd
	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust	1394677	usd
	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust	1575497	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	636419	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	815850	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1394677	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1575497	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	252462	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	616296	usd
	us-gaap	Net Income Loss NetIncomeLoss	742291	usd
	us-gaap	Net Income Loss NetIncomeLoss	1228021	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4312077	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4312077	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6600000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6600000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4525784	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4525784	shares
CY2024Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6600000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6600000	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2024Q2	TENK	Weighted Average Ordinary Shares Outstanding Basic For Ordinary Shares Not Subject To Redemption WeightedAverageOrdinarySharesOutstandingBasicForOrdinarySharesNotSubjectToRedemption	2341000	shares
CY2024Q2	TENK	Weighted Average Ordinary Shares Outstanding Diluted For Ordinary Shares Not Subject To Redemption WeightedAverageOrdinarySharesOutstandingDilutedForOrdinarySharesNotSubjectToRedemption	2341000	shares
CY2023Q2	TENK	Weighted Average Ordinary Shares Outstanding Basic For Ordinary Shares Not Subject To Redemption WeightedAverageOrdinarySharesOutstandingBasicForOrdinarySharesNotSubjectToRedemption	2416000	shares
CY2023Q2	TENK	Weighted Average Ordinary Shares Outstanding Diluted For Ordinary Shares Not Subject To Redemption WeightedAverageOrdinarySharesOutstandingDilutedForOrdinarySharesNotSubjectToRedemption	2416000	shares
	TENK	Weighted Average Ordinary Shares Outstanding Basic For Ordinary Shares Not Subject To Redemption WeightedAverageOrdinarySharesOutstandingBasicForOrdinarySharesNotSubjectToRedemption	2341000	shares
	TENK	Weighted Average Ordinary Shares Outstanding Diluted For Ordinary Shares Not Subject To Redemption WeightedAverageOrdinarySharesOutstandingDilutedForOrdinarySharesNotSubjectToRedemption	2341000	shares
	TENK	Weighted Average Ordinary Shares Outstanding Basic For Ordinary Shares Not Subject To Redemption WeightedAverageOrdinarySharesOutstandingBasicForOrdinarySharesNotSubjectToRedemption	2416000	shares
	TENK	Weighted Average Ordinary Shares Outstanding Diluted For Ordinary Shares Not Subject To Redemption WeightedAverageOrdinarySharesOutstandingDilutedForOrdinarySharesNotSubjectToRedemption	2416000	shares
CY2024Q2	TENK	Basic Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption BasicNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.04
CY2024Q2	TENK	Diluted Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption DilutedNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.04
CY2023Q2	TENK	Basic Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption BasicNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.07
CY2023Q2	TENK	Diluted Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption DilutedNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.07
	TENK	Basic Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption BasicNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.11
	TENK	Diluted Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption DilutedNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.11
	TENK	Basic Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption BasicNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.14
	TENK	Diluted Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption DilutedNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.14
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1987562	usd
CY2024Q1	TENK	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption	958258	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	489829	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-2455991	usd
CY2024Q2	TENK	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption	836421	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	252462	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-3039950	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	345508	usd
CY2023Q1	TENK	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption	759647	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	611725	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	197586	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	197586	usd
CY2023Q2	TENK	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption	818850	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	616296	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-1968	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-1968	usd
	us-gaap	Net Income Loss NetIncomeLoss	742291	usd
	us-gaap	Net Income Loss NetIncomeLoss	1228021	usd
	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust	1394677	usd
	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust	1575497	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	15272	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3643	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	109862	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	82064	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-557796	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-269055	usd
	TENK	Proceeds From Cash Withdrawn From Trust Account ProceedsFromCashWithdrawnFromTrustAccount	25207434	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	400001	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24807433	usd
	TENK	Payments For Relation To Redemptions Of Ordinary Shares PaymentsForRelationToRedemptionsOfOrdinaryShares	25207434	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	400001	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	525311	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	349975	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-24282122	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	349975	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-32485	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	80920	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32746	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	289175	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	261	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	370095	usd
	TENK	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption	1794679	usd
	TENK	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption	1575497	usd
CY2022Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	67320000	usd
CY2022Q4	TENK	Condition For Future Business Combination Use Of Proceeds Percentage ConditionForFutureBusinessCombinationUseOfProceedsPercentage	0.80	pure
CY2022Q4	TENK	Condition For Future Business Combination Threshold Percentage Ownership ConditionForFutureBusinessCombinationThresholdPercentageOwnership	0.50	pure
CY2022Q4	TENK	Redemption Limit Percentage Without Prior Written Consent RedemptionLimitPercentageWithoutPriorWrittenConsent	0.15	pure
CY2022Q4	TENK	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
CY2022Q4	TENK	Maximum Allowed Dissolution Expenses MaximumAllowedDissolutionExpenses	100000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2287923	shares
CY2024Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	6653077	shares
CY2024Q2	us-gaap	Payments For Deposits PaymentsForDeposits	66667	usd
CY2024Q2	TENK	Investments Held In Trust Account InvestmentsHeldInTrustAccount	49152639	usd
CY2023Q4	TENK	Investments Held In Trust Account InvestmentsHeldInTrustAccount	72565394	usd
CY2022Q4	us-gaap	Payments For Deposits PaymentsForDeposits	66667	usd
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.03
CY2022Q4	us-gaap	Share Price SharePrice	10.00
CY2023Q4	TENK	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.03
CY2023Q4	TENK	Temporary Equity Carrying Amount Subject To Possible Redemption TemporaryEquityCarryingAmountSubjectToPossibleRedemption	72565394	usd
	TENK	Offering Costs Allocated Ordinary Shares Subject To Redemption OfferingCostsAllocatedOrdinarySharesSubjectToRedemption	-25207434	usd
	TENK	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption	1794679	usd
CY2024Q2	TENK	Temporary Equity Carrying Amount Subject To Possible Redemption TemporaryEquityCarryingAmountSubjectToPossibleRedemption	49152639	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zyUEkqh3rhjf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zJgLEKmMadMb">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_c20240630_zBPpgEjqH1a5" title="FDIC insured amount">250,000</span>. The Company has not experienced losses on this account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	12.00
CY2024Q2	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	30000	usd
CY2023Q2	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	30000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	120000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	60000	usd
CY2024Q2	us-gaap	Share Price SharePrice	10.00
CY2023Q3	us-gaap	Payments For Deposits PaymentsForDeposits	660000	usd
CY2023Q4	us-gaap	Payments For Deposits PaymentsForDeposits	660000	usd
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Holders of ordinary shares are entitled to one vote for each share.
CY2024Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	2341000	shares
CY2024Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	2341000	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	2341000	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	2341000	shares
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	225000	shares
CY2022Q4	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	2922480	usd

Files In Submission

Name	View Source	Status
0001493152-24-030991-index-headers.html	Edgar Link	pending
0001493152-24-030991-index.html	Edgar Link	pending
0001493152-24-030991.txt	Edgar Link	pending
0001493152-24-030991-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending
tenk-20240630.xsd	Edgar Link	pending
tenk-20240630_def.xml	Edgar Link	unprocessable
tenk-20240630_lab.xml	Edgar Link	unprocessable
tenk-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
tenk-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTOR
CITIUS ONCOLOGY, INC. Stock $ctor

2024 Q3 Form 10-Q Financial Statement

#000149315224030991 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTOR CITIUS ONCOLOGY, INC. Stock $ctor

2024 Q3 Form 10-Q Financial Statement

#000149315224030991 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTOR
CITIUS ONCOLOGY, INC. Stock $ctor